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The K-ras proto-oncogene is activated by point mutation in a wide
variety of human and experimental carcinomas (Barbacid, 1987;
Bos, 1989). Like others, we have reported that, in lung carci-
nomas, K-ras mutations were exclusively found in adenocarci-
nomas (Urban et al, 1996), with a frequency of 30% in smokers
and 5% in non-smokers (Slebos et al, 1991), with more than 90%
of K-ras mutations occurring in codon 12 (Barbacid, 1987; Slebos
et al, 1991). In contrast, in another series, K-ras mutations were
not only detected in adenocarcinomas, but also in squamous cell
carcinomas (Rosell et al, 1993; Behn et al, 1998).
Experimental models of lung tumours conducted in various
mouse strains with various chemical carcinogens (You et al 1989,
1993; Mass et al, 1993) and human data suggest that codon 12 of
K-ras gene may be a target for the mutagenic activity of various
tobacco smoke compounds (Sugio et al, 1992; Husafvel-
Pursiaisen et al, 1993; Westra et al, 1993). K-ras mutation has
been shown to be a preneoplastic event in colonic and probably
pancreatic carcinogenesis (Loeb et al, 1984; Burmer and Loeis,
1989; Yanagisawa et al, 1993; Berthelemy et al, 1995; Brentall et
al, 1995; Tada et al, 1996; Wilentz et al, 1998). Little is known
about preneoplastic events in bronchopulmonary carcinogenesis,
but K-ras and p53 mutations have been shown to occur early in the
development of pulmonary adenocarcinoma (Sozzi et al, 1992;
Sundaresen et al, 1992; Benett et al, 1993; Li et al, 1994). Loss of
heterozygosity of 3p14 loci is also frequently observed in normal
or metaplastic bronchial epithelium in smokers and ex-smokers
(Mao et al, 1997).
The cellular targets for the carcinogenic compounds of tobacco
smoke are usually considered to be either the bronchial mucosa or
alveolar epithelium (Carney, 1991). In a previous study, testing the
hypothesis of the presence of widespread target cells containing
K-ras mutations in the respiratory tract, we did not find any
mutation of codon 12 of the K-ras gene in non-neoplastic distal
bronchial or parenchymal tissues in patients with lung adenocarci-
noma (Urban et al, 1996). Similarly, in a recent report comparing
neoplastic tissue and contralateral bronchial mucosa, the authors
failed to detect K-ras mutations in non-neoplastic cells (Behn et al,
1998). In contrast, Clements et al (1995) reported K-ras mutations
in non-malignant bronchial tissue in some patients with lung
adenocarcinomas.
Bronchial carinae are the main sites of impaction of airborne
contaminants such as tobacco smoke compounds (Knudson, 1960;
Auerbach et al, 1979). It can be hypothesized that these areas may
constitute targets for the genotoxic effects induced by carcinogenic
compounds, such as K-ras gene mutations. As a preliminary step
to test this hypothesis, we therefore investigated the occurrence of
K-ras mutations in non-neoplastic bronchial carinae from a series
of patients with lung adenocarcinomas with and without K-ras
mutations. The study was performed on non-neoplastic bronchial
carinae collected from lungs after thoracotomy for primary lung
adenocarcinomas in 19 patients.
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Summary K-ras activation by point mutation in codon 12 has been reported in lung adenocarcinomas in various models of experimental lung
tumours induced by chemical carcinogens. The hypothesis of the presence of cells containing K-ras mutation in non neoplastic bronchial
carina, the main site of impaction of airborne contaminants, was investigated by evaluating concurrent lung tumour and non-neoplastic
proximal bronchial carinae from 19 patients with lung adenocarcinomas. The restriction fragment length polymorphism enriched PCR method
used can detect one mutant allele among 103 normal alleles. A mutation was detected in 42% of lung adenocarcinoma samples. No mutation
was detected in either tumour or bronchial carinae in nine patients (47%). K-ras mutation was detected in the lung tumour but not in bronchial
carinae in four patients (21%), in both the lung tumour and bronchial carinae in four other patients (21%). In two patients (11%), K-ras
mutation was detected in at least one bronchial carina, but not in the lung tumour. Mutations of codon 12, confirmed by sequencing analysis
of ten samples, were G to T transversion, mostly TGT and GTT in bronchial carinae and lung tumours. Our data show that activated
K-ras by point mutation can be present in non-neoplastic bronchial carina mucosa even when no mutation is detected in tumour samples.
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MATERIALS AND METHODS
Tissue specimens
Lung specimens from 19 patients with lung adenocarcinomas were
evaluated (Tables 1 and 2). All patients underwent preoperative
staging and bronchoscopy with serial carinal biopsies for histo-
logical staging as a routine procedure. All but one (patient 13) of
the patients were smokers or ex-smokers.
All tissue samples investigated in the present study were
collected from specimens obtained after thoracotomy performed
for curative intent with a curative resection, i.e. lobectomy or
pneumonectomy. This study was therefore conducted in accor-
dance with the rules of the Ethical Committee of our institution.
The resected lung was rapidly transported to the Pathology
Department. After examination by the pathologist, non-neoplastic
bronchial carina specimens away from the primary tumour, either
from the same lobe in the case of lobectomy (n = 14) or if possible
from another lobe in the case of pneumonectomy (n = 5), were
collected and snap-frozen at – 70°C until analysis. The standard
bronchial nomenclature was used to localize the tumour and
carinae (Kitamura and Kobayashi, 1995). Only specimens from
lungs containing a tumour situated away from the non-neoplastic
carina were sampled. A representative part of the tumour was also
snap-frozen and stored at –70°C until analysis. Tissue samples
were embedded in paraffin wax for histological analysis and
classified according to the WHO classification into adenocarci-
nomas. To increase the sensitivity of our method of detection of
codon 12 K-ras mutations, macroscopically neoplastic tissue and
bronchial carina were studied under a dissection microscope for
DNA extraction.
Control cell lines
HT29 (homozygous for the wild K-ras gene codon 12, glycine,
GGT) and SW480 (homozygous for a mutated K-ras gene codon
12, valine, GTT) human colon carcinoma cell lines were obtained
from the American Type Culture Collection (ATCC, Rockville,
MD, USA). Tumour DNA with pre-determined codon 12 muta-
tions identified by sequencing was also used as control DNA.
Enriched PCR/RFLP analysis
K-ras codon 12 sequences were amplified (Perkin-Elmer Cetus
thermal cycler) by an enriched polymerase chain reaction (PCR)–
restriction fragment length polymorphism (RFLP) method, as
previously reported (Kahn et al, 1991; Urban et al, 1996).
First-step amplification
The first PCR reaction used a K-ras 5¢ primer (5¢ ACT GAA TAT
AAA CTT GTG GTA GTT GGA CCT 3¢) containing a C substitu-
tion at the first position of codon 11 creating a BstNI site which
overlaps the first two nucleotides of codon 12, and K-ras 3¢ wide-
type (wt) primer (5 TCA AAG AAT GGT CCT GCA CC 3¢) (part
of exon 1 of K-ras gene). Fifteen cycles of a PCR reaction were
performed with an annealing temperature of 56°C with the
following reagents: 50 mM potassium chloride, 10 mM Tris–HCl
pH 8.3, 1.5 mM magnesium chloride, 0.2 mM dNTPs, 2.5 units of
Taq DNA polymerase (Boehringer Mannheim, France), and 10 ng
each of K-ras 5¢ and K-ras 3¢ wt primers.
Intermediate digestion
Five-microlitre aliquots of the first PCR reaction were digested
with 10 units of the restriction enzyme BstNI (Boehringer
Table 1 Localization and presence of mutated K-ras gene (codon 12) in lung primary adenocarcinomas with their corresponding non-neoplastic carinae and
the results of sequence of K-ras gene (codon 12) mutation
Lung adenocarcinomas Non-neoplastic bronchial samples
Localization Codon 12 K-ras Localization (same side) Codon 12 K-ras
No. RFLP Sequence RFLP Sequence
Group 1
1 Apical of apicodorsal (left upper lobe) Mutated GTT Upper lobe division carina Wild –
2 Right upper bronchus Mutated  GTT Proximal carina Wild –
3 Peripheral in ventrobasal (left lower lobe) Mutated  TGT Lower segment carina Wild –
Lower lobe bronchus Wild –
Lower subsegmental carina –
4 Peripheral (right lower lobe) Mutated TGT Segment carina Wild –
Subsegment carina Wild –
Subsegment carina Wild –
Group 2
5 Peripheral (left lower lobe) Mutated – Segment carina Mutated –
Segment carina Mutated –
6 Right upper lobar bronchus Mutated – Upper lobe carina Wild –
Segment carina Mutated –
Segment carina Mutated –
Middle lobe carina Wild –
7 Peripheral (apical of left lower lobe) Mutated TGT Segment carina Wild GGT
Segment carina Mutated TGT
Lower lobe bronchus section Wild GGT
8 Peripheral (apical of left upper lobe) Mutated TGT Upper lobe bronchus Wild GGT
Segmental carina Wild GGT
Segmental carina (bis) Mutated TGT
aHistologically normal; –, not done414 T Urban et al
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Mannheim, France) in a final volume of 10 ml, at 37°C for 1 h
under conditions recommended by the supplier.
Second-step amplification
One microlitre of digested mixture was diluted to a final volume of
50 ml as described above. Primer concentrations were 150 ng each
of K-ras 5¢ (as described above) and K-ras 3¢ primers (5¢ TCA
AAG AAT GGT CCT GGA CC3¢), which also contain a substitu-
tion creating a control BstNI site. Amplification was performed for
30 cycles, as described above. Thirty-microlitre aliquots obtained
after this second step were snap-frozen at –30°C for further
analysis.
RFLP analysis
Twenty-microlitre aliquots of the PCR products obtained after the
second step were digested with 10 units of the restriction enzyme
BstNI, at 37°C for 2 h in a final volume of 40 ml. The results were
analysed by 8% polyacrylamide electrophoresis followed by
ethidium bromide staining and UV transillumination. All speci-
mens were re-evaluated in a second separate PCR amplification.
Codon 12 sequences
Nucleotide sequences of ten mutated K-ras codon 12 detected
after enriched PCR/RFLP analysis were determined by either a
Genetic Analyser or specific oligonucleotide hybridization
according to Hruban et al (1993). Twenty samples without K-ras
mutation were also sequenced as controls.
Sequencing was performed with purified PCR/RFLP products
obtained immediately after the second PCR amplification step
(as described above) without second BstNI reaction. Cycle
sequencing was performed using the ABI PRISM™ dRhodamine
Terminator Cycle Sequencing Ready Reaction Kit with
AmpliTaq® DNA polymerase FS (Applied Biosystems, Paris) in
a GeneAmp PCR systems 9600 (Perkin-Elmer). The precipitated
pellets were resuspended in Template Suppression Reagent®
(Applied Biosystems, Paris, France), denatured and electro-
phoresed on the ABI Prism 310 Genetic Analyser. The PCR
product sequence was analysed with ABI PRISM™ software.
Oligonucleotide sequences, hybridization conditions in ammo-
nium tetramethylchloride, specific washing conditions and compo-
sition of the probes used have been previously described by
Wilentz et al (1998).
RESULTS
Patients
Nineteen patients with lung adenocarcinomas were studied. Non-
neoplastic bronchial carina samples were available in all 19
patients, as reported in Tables 1 and 2. Surgical resection consisted
of lobectomy (n = 14) or pneumonectomy (n = 5). Eight patients
presented an endobronchial tumour diagnosed during a bron-
choscopy procedure, whereas 11 patients had a peripheral lung
tumour, mainly in a subpleural site. The tumours were classified
according to the TNM classification as stage I (11/19), stage II
(2/19), stage III (4/19) or stage IV (2/19). Two patients were
classified as stage IV because of isolated cranial metastasis and
underwent complete neurosurgical resection.
Table 2 Localization of lung primary adenocarcinomas with wild-type K-ras gene (codon 12) with their corresponding non-neoplastic carinae and the results of
mutated K-ras gene (codon 12) detection
Lung adenocarcinomas Non-neoplastic bronchial carinae
Localization Codon 12 K-ras Localization (same side) Codon 12 K-ras
No. RFLP Sequence RFLP Sequence
Group 3
9 Ventral of right upper lobe Wild GGT Segment carina Mutated GTT
Segment carina Wild GGT
10 Apical of right lower lobe Wild GGT Upper lobe carina Mutated –
Upper lobe carina Mutated TGT
Middle lobe carina Wild GGT
Lower lobe carina Wild GGT
Group 4
11a Laterobasal of left lower lobe Wild GGT Segment carina Wild GGT
Segment carina Wild GGT
12 Laterodorsobasal of left lower lobe Wild GGT Segment carina Wild GGT
Segment carina Wild GGT
13b Left upper bronchus Wild – Main bronchus Wild –
Wild –
14 Peripheral (right upper lobe) Wild GGT Segment carina Wild –
15 Peripheral (right upper lobe) Wild GGT Subsegmental carina Wild –
16 Peripheral (left upper lobe) Wild GGT Upper lobe bronchus carina Wild –
17 Peripheral (right lower lobe) Wild GGT Proximal lobe carina Wild –
18 Peripheral (dorsal of right upper lobe) Wild – Upper lobe carina Wild –
Upper segment carina Wild –
Upper subsegment carina Wild –
19 Peripheral (apical of right upper lobe) Wild – Upper lobe carina Wild GGT
Truncus intermedius Wild GGT
aAdenosquamous lung carcinoma; bnon-smoker patient; –, not doneEnriched PCR/RFLP method
SW480 and HT29 human colon carcinoma cell lines were used to
validate our PCR/RFLP method. Amplification of the K-ras codon
12 sequence gave a 157 bp fragment before BstNI digestion. After
the two-step procedure described above, digestion of wild-type
codon 12 sequence (HT29 cell line DNA) with BstNI generated a
114 bp fragment, while, when a mutation was present in codon 12
(SW480 cell line DNA), BstNI digestion generated a 143 bp frag-
ment, as shown in Figure 1. The presence of a 143 bp fragment
after digestion is therefore the hallmark of the presence of mutated
K-ras genes on codon 12.
Analysis of a mixture of DNA from the two cell lines showed
two fragments of 143 and 114 bp respectively. The sensitivity of
the assay was therefore controlled by a series of titration experi-
ments. The limit of detection was 1 cell with homozygous muta-
tion within a minimum of 103 cells with a wild-type K-ras gene, as
previously reported (Urban et al, 1996).
Detection of codon 12 c-K-ras mutations in patient
samples
The detailed results are shown in Tables 1 and 2. A mutation in
codon 12 of the K-ras gene was observed in eight of the 19 lung
adenocarcinomas (42%) (Tables 1 and 2). A mutation in codon 12
of the K-ras gene was observed in nine of the 41 non neoplastic
bronchial carina samples evaluated (22%), i.e. in six of the 19
patients (32%) (Tables 1 and 2).
Lung tumour and non-neoplastic carinae
Four different patterns were observed, expressed as groups 1, 2, 3
and 4 (Tables 1 and 2).
In group 1: (patients 1–4), a K-ras mutation was detected in
lung tumours, but not in bronchial carinae (Table 1).
In group 2: (patients 5–8), K-ras mutations were detected in
lung tumours and in bronchial carina samples collected away from
the tumour. It must be stressed that, for patient 6, presenting a
tumour located in the right upper lobe, no mutation was detected in
the upper lobe carina, but a K-ras gene mutation was detected in
the apical carina of the right lower lobe (Table 1).
In group 3: (patients 9 and 10), no mutation was detected in the
tumours of these two patients, despite multiple (n = 3) evaluation
by enriched PCR/RFLP, but mutations were present in bronchial
carinae (Table 2).
In group 4: (patients 11–19), no mutation was detected in either
lung tumour or bronchial carina samples (Table 2).
Codon 12 sequences
Detailed data are reported in Table 2. The type of codon 12 K-ras
mutations was always G to T transversions, TGT and GTT, in both
carina and lung tumours (Figure 2).
DISCUSSION
The method used to detect mutation in the 12th codon of the K-ras
gene was a combination of PCR DNA amplification and RFLP
analysis (Jiang et al, 1989; Urban et al, 1993). This method is
highly specific, as loss of the restriction site at the target is diag-
nostic for the presence of a mutation (Jiang et al, 1991; Urban et al,
1996; Behn et al, 1998). The enriched PCR/RFLP procedure is
able to detect one mutated allele among 103 normal alleles, while a
one-step PCR/RFLP analysis is only able to detect a K-ras muta-
tion present in 1% of cells studied (Urban et al, 1996). Used as a
control of this method, specific oligonucleotide hybridization gave
similar results in previously published experiments (Urban et al,
1996).
In the present series of 19 lung adenocarcinomas, activated
protooncogene K-ras by mutation on codon 12 was observed in
eight lung adenocarcinomas (42%), as already reported previously
(Rodenhuis et al, 1988; Slebos et al, 1990; Urban et al, 1996).
However, similar results have been recently reported; for example
Ronai et al (1996) detected K-ras mutation in 48% of a series of
non-small-cell lung carcinomas.
Detection of K-ras mutations in bronchial carina 415
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Figure 1 Enriched PCR amplification and RFLP analysis. Photograph of
DNA electrophoresis through an 8% polyacrylamide gel after ethidium
bromide staining and UV analysis. Left and right lanes: molecular weight
markers. The base pair number is indicated in the right margin. Lanes 1–4:
Bst NI digestion of PCR product after amplification of DNA from three
bronchial carina samples and lung adenocarcinoma sample with wild-type
codon 12 showing a single 114 bp fragment. Lane 6: Bst NI digestion of PCR
product after amplification of DNA from bronchial carina sample (patient no.
7) with wild-type codon 12 showing a single 114 bp fragment. Lane 5 and 7:
BSTNI digestion of PCR product after amplification of DNA from samples
from bronchial carina and lung adenocarcinoma (patient no. 7) with
heterozygous mutation, showing 114 and 143 fragments. Lane 8: PCR
product after amplification of DNA from lung adenocarcinoma (patient no. 7),
before BstNI digestion, showing a single 157 bp fragment.
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Figure 2 Characterization of K-ras mutations by sequencing analysis.
Shown is the sequence of codon 12 in 3 samples: (A) wild type K-ras (GGT);
(B) mutated K-ras (GTT); (C) presence of wild-type (GGT) and mutated
(TGT) K-ras alleles in the DNA sample416 T Urban et al
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K-ras mutation has been shown to be a preneoplastic event in
colonic and pancreatic carcinogenesis (Burmer and Loeb, 1989;
Yanagisawa et al, 1993; Berthelemy et al, 1995; Brentall et al,
1995; Tada et al, 1996; Wilentz et al, 1998). Moreover, when using
an enriched PCR method, K-ras mutations were detected in
normal colonic mucosa away from the tumour (Minamoto et al,
1995). K-ras mutations have also been detected in mucous hyper-
plasia of pancreatic ducts associated with pancreatitis, suggesting
that they may be precancerous epithelial changes in the patho-
genesis of pancreatic carcinomas (Yanagisawa et al, 1993).
In contrast, data concerning preneoplastic events in bronchopul-
monary carcinogenesis are more recent and incomplete. p53 muta-
tions have been shown to occur very early in the development of
lung adenocarcinomas (Sozzi et al, 1992; Sundaresen et al, 1992;
Benett et al, 1993; Li et al, 1994), and a linkage with tobacco
smoke exposure has been clearly established with the presence of
genetic abnormalities in the p53 gene (Denissenko et al, 1996). In
a recent study based on serial bronchial biopsies, Mao et al (1997)
reported a high frequency of genetic abnormalities of the 3p14 loci
(FHIT 3p14.2 gene) and, less frequently, of the 9p21 loci (p16
gene) and 17p13 loci (p53 gene) in normal and metaplastic
bronchial epithelium sampled in smokers and non-smokers. Loss
of heterozygosity of 3p14 chromosome was observed in 88% of
smokers and 45% of ex-smokers, but was a very rare event in non-
smokers, and was more frequently observed in the case of a high
metaplastic index. This observation suggested a linkage with
tobacco smoke exposure and potential reversibility of 3p14 genetic
abnormalities in ex-smokers. In contrast, the early occurrence of
K-ras mutation is still controversial as for some authors it is
considered as a late event in the carcinogenesis of lung tumours
(Sugio et al, 1994). However, our results as well as those pre-
viously reported by Clements et al (1995) suggest that K-ras muta-
tion could be an earlier event than usually considered.
The cellular targets for the carcinogenic compounds of tobacco
smoke are usually considered to be either the bronchial mucosa or
alveolar epithelium (Carney, 1991). The hypothesis of the pres-
ence of widespread target cells containing K-ras mutations in the
respiratory tract, as already shown for the affected suppressor gene
p53, therefore had to be considered (Sozzi et al, 1992; Sundaresen
et al, 1992; Benett et al, 1993; Li et al, 1994). We previously tested
this hypothesis by evaluating distal tissues, i.e. non-proximal
bronchial or parenchymal tissues, but failed to find any mutations
on codon 12 of the K-ras gene in these tissues, in patients with
lung cancers (Urban et al, 1996). In 1995, Clements et al reported
K-ras mutations in non-malignant bronchial tissues collected
under fibreoptic bronchoscopic examination in patients with non-
small-cell lung carcinomas (Clements et al, 1995). We therefore
hypothesized that such a discrepancy between these results (Li et
al, 1994; Urban et al, 1996; Behn et al, 1998) could be explained
by the fact that the samples studied by Clements et al were
collected from proximal bronchial carinae, which are the main
sites of impaction of tobacco smoke compounds, shown to be the
site of epithelial changes in response to constant exposure to
airborne contaminants (Knudson, 1960; Auerbach et al, 1979).
The present study shows that K-ras gene mutations in codon 12
can be present in non-neoplastic bronchial carina in patients with
lung adenocarcinomas. These mutations were detected either away
from a tumour harbouring a K-ras mutation, but also in two
patients not presenting any mutation in the carcinoma, despite
multiple evaluations by enriched PCR/RFLP, confirmed by
sequencing analysis. This finding clearly demonstrates that the
presence of mutated K-ras, at least in these three cases, was not
related to a theoretical possibility of endobronchial contamination
by tumour cells.
Codon 12 mutations were found to be G to T transversions,
mostly TGT and GTT, in carina samples and lung tumours. These
results are in accordance with previous studies (Kobayashi et al,
1990; Westra et al, 1993; Rodenhuis et al, 1997). Benzo(a)pyrene,
and nitrosamines, considered to be the major carcinogenic
compounds of tobacco smoke (Loeb et al, 1984; Carothers, 1990),
have been demonstrated to induce mostly G to T transversion in
experimental murine models of lung tumours harbouring a K-ras
mutation restricted to codon 12 (You et al, 1989, 1993; Mass et al,
1993).
The significance of K-ras activation in lung carcinogenesis
therefore remains to be elucidated. One hypothesis is that such a
mutation could be a marker of exposure to tobacco smoke carcino-
genic compounds in patients at risk for lung adenocarcinoma. In
fact, in experimental murine lung tumour models performed in F1
littermates from susceptible and resistant parents, it has been
shown that codon 12 mutations affect the K-ras allele from the
susceptible parent (You et al, 1992). It has also recently been
shown that K-ras polymorphism associated with two other poly-
morphic markers from chromosome 12p was associated with a risk
of lung adenocarcinoma (Manenti et al, 1997).
In conclusion, mutated K-ras can be detected in non-neoplastic
bronchial mucosa, particularly bronchial carina, which is the main
site of impaction of airborne contaminants such as tobacco smoke
compounds. The results of this study now need to be confirmed by
a larger study conducted in smokers and non-smokers with or
without various types of lung carcinomas.
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